The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Kezar Life Sciences Stock A Buy?
Kezar Life Sciences stock has been rallying off the bottom of a steep correction, but is trading just below its 200-day moving average. While it's not currently an ideal time to buy shares, see if the stock is able to establish and enter a buying range in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
In terms of fundamentals, the biotech firm has posted rising EPS growth in each of the last two reports. Revenue gains have been a different story, coming in at 0% in the most recent report.
Kezar Life Sciences stock earns the No. 126 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics and Dynavax Technologies are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
